MT Newswires After-Hours News Movers
5:54PM ET 10/21/2019 MT NewswiresSome of the stocks moving on news-driven events in Monday's after-hours include: NLNK, +7.38% AMTD, +5.31% CDNS, +4.84% WSFS, +1.79% UPS, +1.58% ZION,...
Quotes Snapshot > VCYT
Veracyte Inc VCYT:NASDAQ
Next Earnings date is expected on
10/22/2019
Last Price$26.19NASDAQ Previous Close - Last Trade as of 4:00PM ET 10/21/19
Today's Change+1.52(6.16%)
Bid (Size)$26.16 (1)
Ask (Size)$26.67 (88)
Day Low / High$24.60 - 26.30
Volume962.0 K
Read more news Recent News
Veracyte's Data Shows Validity and Utility of Percepta Classifier in Lung Cancer Diagnosis
5:11PM ET 10/21/2019 MT NewswiresVeracyte (VCYT) said on Monday data showed the clinical validity of its next-generation Percepta Genomic Sequencing Classifier (GSC) and the clinical...
Insider Trends: Insider at Veracyte Converts Options in Mist of 90-Day Buying Trend
4:08PM ET 9/20/2019 MT NewswiresOn Sep 18, 2019, Keith Kennedy, COO / CFO, exercised options for 22,365 shares in Veracyte (VCYT) for $167,067. Kennedy, subsequent to the transactions...
Insider Trends: Veracyte Insider Extends 90-Day Selling Trend
5:47PM ET 9/12/2019 MT NewswiresBonnie H Anderson, Director and Chairman & CEO, sold 8,000 shares of Veracyte (VCYT) on Sep 10, 2019, for $196,114. Subsequent to the Form 4 filing with...
View all Commentary and Analysis
Fiera Capital SMID Cap Growth Strategy Q3 2019 Commentary
11:45AM ET 10/21/2019 Seeking AlphaVeracyte: Exceeding Expectations In Genomic Testing
10:05AM ET 9/30/2019 Seeking AlphaBulletproof Investing Performance Update: Week 95
12:23PM ET 9/26/2019 Seeking AlphaVeracyte (VCYT) Presents At Morgan Stanley 17th Annual Global Healthcare Conference - Slideshow
3:37PM ET 9/11/2019 Seeking AlphaCompany Profile
Business DescriptionVeracyte, Inc. engages in the research, development, and commercialization of diagnostic products. Its portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA. View company web site for more details
| Address | 6000 Shoreline Court South San Francisco, California 94080 |
| Phone | +1.650.243.6300 |
| Number of Employees | 270 |
| Recent SEC Filing | 10/11/2019 4 |
| Chairman & Chief Executive Officer | Bonnie H. Anderson |
| Chief Operating & Financial Officer | Keith Kennedy |
| Chief Scientific & Medical Officer | Giulia C. Kennedy |
| Chief Information Officer | Ashish Kheterpal |
Company Highlights
| Price Open | $24.84 |
| Previous Close | $26.19 |
| 52 Week Range | $9.20 - 31.18 |
| Market Capitalization | $1.3 B |
| Shares Outstanding | 48.4 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 10/22/2019 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$0.29 |
| Beta vs. S&P 500 | N/A |
| Revenue | $92.0 M |
| Net Profit Margin | -11.01% |
| Return on Equity | -10.26% |
Analyst Ratings as of 07/31/2019
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |